Tasly Pharmaceutical Group Co., Ltd (SHA: 600535)

Tasly Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	3,636	4,451	3,119	2,304	1,976	1,891
Trading Asset Securities	1,332	300.71	1,125	1,487	142.92	59.39
Cash & Short-Term Investments	4,968	4,751	4,244	3,791	2,119	1,950
Cash Growth	13.35%	11.95%	11.95%	78.94%	8.63%	-37.83%
Accounts Receivable	2,200	2,131	3,348	3,796	5,198	11,138
Other Receivables	86.55	11.49	8.98	9.47	421.43	208.63
Receivables	2,286	2,142	3,357	3,805	5,619	11,347
Inventory	1,708	1,748	1,532	1,548	1,354	2,547
Other Current Assets	109.29	91.43	127.08	105	145.92	699.16
Total Current Assets	9,072	8,733	9,260	9,249	9,237	16,543
Property, Plant & Equipment	3,641	3,769	3,883	4,088	3,881	4,011
Long-Term Investments	1,850	2,054	1,511	1,229	1,535	1,209
Goodwill	15.88	15.88	15.88	167.08	15.88	143.24
Other Intangible Assets	596.48	573.64	459.43	474.54	361.4	408.71
Long-Term Deferred Tax Assets	39.65	50	88.29	60.79	42.82	119.92
Long-Term Deferred Charges	1,560	1,476	1,157	1,193	1,412	1,579
Other Long-Term Assets	60.14	43.14	102.08	79.68	8.45	0.45
Total Assets	16,835	16,714	16,477	16,542	16,494	24,014
Accounts Payable	1,093	497.12	757.15	603.79	572.52	2,747
Accrued Expenses	86.34	178.72	242.79	213.15	200.28	230.25
Short-Term Debt	993.29	814.63	201.77	188.79	638.73	2,719
Current Portion of Long-Term Debt	875.71	462.39	475.21	343.33	1,137	2,207
Current Portion of Leases	-	58.54	53.98	55.67	-	-
Current Income Taxes Payable	97.39	18.04	84.62	108.09	34.6	86.02
Current Unearned Revenue	86.17	91.62	92.35	68.33	26.82	-
Other Current Liabilities	128.76	248.49	239.34	273.91	221.86	668.39
Total Current Liabilities	3,361	2,370	2,147	1,855	2,832	8,657
Long-Term Debt	244.36	1,414	1,376	1,034	1,020	3,233
Long-Term Leases	57.11	81.52	75.31	81.63	-	-
Long-Term Unearned Revenue	153.35	159.02	177.79	214.57	234.56	256.18
Long-Term Deferred Tax Liabilities	0.11	0.11	22.87	42.18	22.55	3.98
Other Long-Term Liabilities	1.42	-	-	-	-	-
Total Liabilities	3,817	4,024	3,799	3,228	4,109	12,150
Common Stock	1,494	1,500	1,500	1,513	1,513	1,513
Additional Paid-In Capital	864.86	958.08	1,457	1,530	2,321	1,991
Retained Earnings	10,278	9,929	9,351	10,222	8,359	7,730
Treasury Stock	-	-105.98	-105.98	-251.29	-194.86	-100.09
Comprehensive Income & Other	70.34	88	211.58	-32.19	-25.1	-1.89
Total Common Equity	12,707	12,368	12,412	12,981	11,972	11,132
Minority Interest	310.55	321.59	265.12	332.56	411.77	732.19
Shareholders' Equity	13,018	12,690	12,678	13,314	12,384	11,864
Total Liabilities & Equity	16,835	16,714	16,477	16,542	16,494	24,014
Total Debt	2,170	2,831	2,182	1,704	2,796	8,158
Net Cash (Debt)	2,797	1,920	2,062	2,088	-677.47	-6,208
Net Cash Growth	197.61%	-6.87%	-1.23%	-	-	-
Net Cash Per Share	1.86	1.29	1.40	1.39	-0.45	-4.09
Filing Date Shares Outstanding	1,494	1,494	1,494	1,499	1,503	1,508
Total Common Shares Outstanding	1,494	1,494	1,494	1,499	1,503	1,508
Working Capital	5,711	6,363	7,113	7,394	6,406	7,886
Book Value Per Share	8.51	8.28	8.31	8.66	7.97	7.38
Tangible Book Value	12,095	11,779	11,937	12,340	11,595	10,580
Tangible Book Value Per Share	8.10	7.88	7.99	8.23	7.71	7.02
Buildings	-	3,505	3,490	3,398	3,239	3,115
Machinery	-	3,625	3,472	3,340	2,974	2,821
Construction In Progress	-	153.87	102.96	167.85	400.97	614.02

Source: S&P Capital IQ. Standard template. Financial Sources.